CG Oncology (NASDAQ: CGON) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.57) by 24.56 percent. This is a 57.78 percent decrease over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $1.083 million which beat the analyst consensus estimate of $493.182 thousand by 119.59 percent. This is a 1.98K percent increase over sales of $52.000 thousand the same period last year.